(Actoxumab)Biosimilar Reference Antibody 新品

货号：GS40009

Actoxumab is a human monoclonal antibody designed as an antitoxin therapeutic. Its primary purpose is the prevention of recurrence of Clostridioides difficile infection (CDI). The antibody works by binding to and neutralizing Clostridioides difficile Toxin A (TcdA), which is one of the two major virulence factors responsible for the pathology of CDI (diarrhea and pseudomembranous colitis). By neutralizing the toxin, Actoxumab prevents it from binding to and damaging the host's intestinal epithelial cells. Actoxumab was often studied and developed in combination with Bezlotoxumab, an antibody targeting C. difficile Toxin B (TcdB). While the combination showed promise, the FDA ultimately approved only Bezlotoxumab (Zinplava) as an antitoxin therapy for CDI recurrence prevention.